Important Legal Notice: Class Action Against ARS Pharmaceuticals for Securities Fraud

Investor Alert: Class Action Filed Against ARS Pharmaceuticals

On October 1, 2026, the Pomerantz Law Firm announced the initiation of a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). This legal action highlights critical issues surrounding potential securities fraud and unlawful business practices within the company. Investors who believe they have incurred losses related to their holdings in ARS are strongly encouraged to reach out to Danielle Peyton at Pomerantz for guidance on participating in this proceedings.

Key Details of the Lawsuit

The lawsuit comes in the wake of alarming revelations regarding the company's flagship product, neffy, an epinephrine nasal spray. On June 24, 2026, ARS disclosed through a press release that it failed to secure expanded insurance coverage for neffy via CVS Caremark by their set deadline of July 1, 2026. Consequently, this omission might significantly affect customers during vital allergy seasons—both summer and back-to-school.

The press release from ARS indicated that the decision on the insurance coverage for their product would not be resolved until January 2027. This delay directly impacted investor confidence, leading to a steep decline in stock price. Following the announcement, ARS's stock plummeted by $2.52 a share (approximately 23.91%), closing at $8.02 on June 25, 2026.

The Impact on Investors

Investors who acquired ARS securities during the class period have until October 5, 2026, to seek appointment as Lead Plaintiff in the ongoing class action. For clarity, those interested in joining or receiving more detailed updates can access a copy of the Complaint through the Pomerantz website or contact the legal firm.

Furthermore: The Legacy of Pomerantz LLP

Pomerantz LLP is heralded for its profound impact on corporate, securities, and antitrust class litigation since it was established over 85 years ago. Founded by Abraham L. Pomerantz, referred to as the 'dean of the class action bar', this firm was pivotal in laying the groundwork for securities class actions. Today, it maintains that legacy, advocating for those impacted by corporate misconduct and securities fraud, achieving numerous multi-million dollar recoveries for its clients.

For ongoing updates or inquiries regarding this case, ARS investors should direct their attention to the law firm’s designated contacts: Danielle Peyton and her team. Investors can contact her by email at [email protected] or through direct phone lines at 646-581-9980 (ext. 7980) or the toll-free 888.4-POMLAW.

Conclusion

In light of these developments, current and past investors of ARS Pharmaceuticals must consider their options regarding participation in this class action. Legal landscapes can shift rapidly, making timely action essential to safeguarding investor rights in situations characterized by potential corporate malfeasance.